UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of November, 2016
Commission File Number:
001-36000
XTL Biopharmaceuticals Ltd.
(Translation of registrant’s name
into English)
5 HaCharoshet St., Raanana,
4365603, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085,
File No. 333-148754 and File No. 333-154795) and Form F-3 (File No. 333-194338).
XTL
BIOPHARMACEUTICALS RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM BID REQUIREMENTS
RAANANA,
Israel
- (November 14, 2016) –
XTL Biopharmaceuticals
Ltd
.
(NASDAQ: XTLB, TASE: XTLB.TA)
(“XTL” or the “Company”),
a clinical-stage biopharmaceutical company developing its lead product for the treatment of autoimmune diseases, today
announced that it received a notice from The NASDAQ Stock Market ("NASDAQ") that the Company is not in compliance with
NASDAQ's Listing Rule 5450(a)(1) because the minimum bid price of the Company's American Depositary Shares (“ADSs”)
has closed below US$1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect
on the listing or trading of the Company's ADSs on The Nasdaq Capital Market.
The Company has
180 days, or until May 8, 2017, to achieve compliance with the minimum bid price requirement. To regain compliance, the minimum
bid price of the Company's ADSs must meet or exceed US$1.00 per share for a minimum of 10 consecutive business days during this
180-day grace period.
If the Company
does not regain compliance with the rule by May 8, 2017, the Company may be eligible for an additional 180 day compliance period.
About XTL Biopharmaceuticals Ltd.
(XTL)
XTL Biopharmaceuticals
Ltd., is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune
diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of
systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some
have significant side effects. hCDR1 has robust clinical data in three clinical trials with 400 patients and over 200 preclinical
studies with data published in more than 40 peer reviewed scientific journals.
XTL is traded
on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following
indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.
About hCDR1
hCDR1 is a novel compound with a unique
mechanism of action and has clinical data on over 400 patients in three clinical studies. The drug has a favorable safety profile,
is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful endpoint. For more information
please see a peer reviewed article in Lupus Science and Medicine journal (http://lupus.bmj.com/content/2/1/e000104.full).
About Systemic Lupus Erythematosus (SLE)
Lupus is a chronic inflammatory autoimmune
disease involving many systems in the human body, including joints, kidneys, central nervous system, heart, hematological system
and others. The biologic basis of the disease is dysregulation of the immune (defense) system, leading to production of self (auto)
antibodies attacking the normal organs and causing irreversible damage. According to the Lupus Foundation of America, at least
1.5 million Americans have the disease (more than 5 million worldwide) with more than 16,000 new cases diagnosed each year. The
majority of patients are women of childbearing years. There has been only one drug approved by the FDA in the last 50 years and
recently two of the few drugs in advanced development did not meet their primary endpoints in Phase 3 trials.
For further information, please contact:
Investor Relations, XTL Biopharmaceuticals
Ltd.
Tel: +972 9 955 7080
Email: ir@xtlbio.com
www.xtlbio.com
Cautionary Statement
This press release may contain forward-looking
statements, about XTL’s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as "believe," "expect," "intend," "plan," "may,"
"should" or "anticipate" or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL’s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
XTL’s actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause XTL’s actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in XTL’s filings with the SEC and
in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile
and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update
these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors
associated with an investment in our ADSs or ordinary shares which are included in our Form F-1/A filed with the U.S. Securities
and Exchange Commission on November 8, 2016.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
XTL BIOPHARMACEUTICALS LTD.
|
|
|
|
Date: November 14, 2016
|
By:
|
/s/ Josh Levine
|
|
|
Josh Levine
|
|
|
Chief Executive Officer
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2024 to Aug 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Aug 2023 to Aug 2024